Skip to main content
. 2024 May 2;26(5):euae112. doi: 10.1093/europace/euae112

Figure 3.

Figure 3

Left—distribution of the responses regarding the therapy of arrhythmia-induced cardiomyopathy. Multiple choices were allowed. Right—distribution of the responses regarding adjuvant heart failure therapy in AICM. Multiple choices were allowed. AICM, arrhythmia-induced cardiomyopathy; ACE, angiotensin conversion enzyme antagonist; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor/neprilysin inhibitor; MRA, mineralocorticoid receptor antagonist.